NEW YORK, Feb 8 – An Israeli holding company said Wednesday it was launching a new subsidiary that would invest in early stage biotech companies, including genomics enterprises.

Elscint, a hotel, leisure, and medical device company, said it would allocate $30 million for Elscint BioMedical.